The cancer anorexia-cachexia syndrome: myth or reality?

被引:32
|
作者
Lasheen, Wael [2 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Cleveland, OH 44195 USA
[2] Taussig Canc Inst, Cleveland Clin, Dept Solid Tumor Oncol, Harry R Horvitz Ctr Palliat Med, Cleveland, OH USA
关键词
Cancer; Cachexia; Anorexia; Anorexia-cachexia; Symptoms; Symptom burden; Survival; Prognosis; Palliative care; MEGESTROL-ACETATE; WEIGHT-LOSS; FOOD-INTAKE; CHEMOTHERAPY; DEFINITION; SYMPTOMS; THERAPY; PLACEBO;
D O I
10.1007/s00520-009-0772-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral). Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (> 10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO > 10% pre-illness weight loss); (3) group WL (weight loss > 10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss > 10% pre-illness weight and NO anorexia). Symptoms present in a parts per thousand yen5%, and patients with complete data were analyzed. Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in a parts per thousand yen5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival. CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 50 条
  • [31] Megestrol acetate for the treatment of anorexia-cachexia syndrome
    Berenstein, EG
    Ortiz, Z
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [32] Megestrol acetate for treatment of anorexia-cachexia syndrome
    Ruiz Garcia, Vicente
    Lopez-Briz, Eduardo
    Carbonell Sanchis, Rafael
    Gonzalvez Perales, Jose Luis
    Bort-Marti, Sylvia
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (03):
  • [33] Mediators involved in the cancer anorexia-cachexia syndrome:: past, present, and future
    Argilés, JM
    Busquets, S
    García-Martínez, C
    López-Soriano, FJ
    NUTRITION, 2005, 21 (09) : 977 - 985
  • [34] Anorexia-Cachexia Syndrome in Pancreatic Cancer: Recent Development in Research and Management
    Uomo, Generoso
    Gallucci, Fernando
    Rabitti, Pier Giorgio
    JOURNAL OF THE PANCREAS, 2006, 7 (02): : 157 - 162
  • [35] Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway
    Camps, Carlos
    Iranzo, Vega
    Bremnes, Roy M.
    Sirera, Rafael
    SUPPORTIVE CARE IN CANCER, 2006, 14 (12) : 1173 - 1183
  • [36] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins
    PHARMACY WORLD & SCIENCE, 2007, 29 (03): : 288 - 289
  • [37] Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
    Yu Bai
    Yunxia Hu
    Yanhua Zhao
    Xizhong Yu
    Junwei Xu
    Zhiyun Hua
    Zhiqiang Zhao
    Supportive Care in Cancer, 2017, 25 : 1651 - 1659
  • [38] Primary tumorous anorexia-cachexia syndrome and forms of intervention
    Jarisch, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 737 - 737
  • [39] Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome
    Fujitsuka, Naoki
    Uezono, Yasuhito
    FRONTIERS IN PHARMACOLOGY, 2014, 5
  • [40] A New Horizon of Herbal Medicines in Anorexia-Cachexia Syndrome
    Inui, Akio
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (31) : 4747 - 4748